Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones sold 2,932 shares of the firm’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the chief financial officer directly owned 37,394 shares in the company, valued at $1,013,003.46. This trade represents a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $27.18 on Monday. The firm has a 50-day moving average of $32.20 and a 200-day moving average of $35.97. The company has a market cap of $1.58 billion, a PE ratio of -3.88 and a beta of 0.89. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.15. The business had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter last year, the firm earned $16.22 EPS. On average, equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. NewEdge Advisors LLC purchased a new position in shares of Agios Pharmaceuticals in the first quarter valued at $40,000. First Horizon Corp bought a new position in Agios Pharmaceuticals in the 3rd quarter worth about $45,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 320 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $79,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the first quarter worth about $133,000.

Analysts Set New Price Targets

AGIO has been the subject of a number of analyst reports. Leerink Partnrs raised Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 20th. Citigroup reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Friday, December 26th. Bank of America increased their price objective on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 24th. The Goldman Sachs Group decreased their target price on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, November 20th. Finally, Royal Bank Of Canada cut shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $57.00 to $28.00 in a report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.